Figure 6.

MB application alters levels of phosphorylated Tau. (a) Levels of total Tau (pan-Tau antibody K9JA), PHF1 phosphorylated (epitope pSer396/pSer404) and 12E8 (epitope pSer262/pSer356) phosphorylated Tau in cortex homogenates of MB-treated and untreated Tau^ΔK mice. MB administration for 14.5mo, 6mo and 3mo results in a decrease of PHF1 phospho-Tau as compared to untreated Tau^ΔK mice. By contrast an increase of 12E8 phospho-Tau inside the repeat domain of Tau is observed after MB treatment, indicating detachment from microtubules. (b) Determination of relative protein densities by quantification of (a). Levels of phosphorylated Tau were normalized to total Tau levels. Bars represent mean values ± SEM. Statistics: one-way analysis of variances with post-hoc Newman-Keuls multiple comparisons test. Asterisks indicate significant differences in comparison to untreated Tau^ΔK mice; *: p < 0.05; n, number of samples.